Understanding Lupus Anticoagulant and APTT Testing

Podcast

Play an AI-generated podcast conversation about this lesson

Questions and Answers

What is the effect of the lupus anticoagulant on clot formation?

It prevents clot formation entirely.

It enhances clot formation speed.

It slows down clot formation. (correct)

It has no effect on clot formation.

What is the characteristic of the lupus anticoagulant (LA)?

It decreases clotting time significantly.

It is a substance that enhances coagulation.

It is an in vivo phenomenon.

It is associated with specific antiphospholipid antibodies. (correct)

In what context does the lupus anticoagulant present a phenomenon?

In chronic illnesses.

In acute infections.

Only in healthy individuals.

In vitro settings. (correct)

What is the purpose of mixing patient PPP with FV deficient substrate?

To enhance the sensitivity of the test Signup and view all the answers

What is likely to occur when the lupus anticoagulant is present?

The clotting time is increased. Signup and view all the answers

What is a common issue associated with indwelling venous devices?

Thrombosis of the lines Signup and view all the answers

What does APTT stand for in the context of blood testing?

Activated Partial Thromboplastin Time Signup and view all the answers

Which of the following is a key feature of the lupus anticoagulant?

It reacts with specific proteins associated with clinical events. Signup and view all the answers

In which patients is thrombosis of indwelling venous lines more likely to occur?

Patients with tips positioned distal to the superior vena cava Signup and view all the answers

What is performed after the standard APTT on the mixture?

A modified APTT on the mixture Signup and view all the answers

What is ACP used for in the testing process?

To evaluate the clotting factor deficiencies Signup and view all the answers

What factor contributes to the acute phase response seen in postoperative patients?

Reduced mobility Signup and view all the answers

Which statement about postoperative patients and acutely ill medical patients is true?

They are at risk for thrombosis due to immobility and other factors. Signup and view all the answers

Why is an equal volume of FV deficient substrate mixed with patient PPP?

To optimize the testing conditions for sensitivity Signup and view all the answers

What is a significant risk factor in the positioning of indwelling venous devices?

Positioning the tip distal to the superior vena cava Signup and view all the answers

What percentage of patients with paroxysmal nocturnal haemoglobinuria (PNH) experience venous thrombosis?

40% Signup and view all the answers

What does paroxysmal nocturnal haemoglobinuria primarily refer to?

A condition affecting the blood and bone marrow Signup and view all the answers

What significant health issue is associated with paroxysmal nocturnal haemoglobinuria?

Venous thrombosis Signup and view all the answers

Which statement is true regarding venous thrombosis in PNH patients?

It can lead to significant morbidity and mortality. Signup and view all the answers

Why is paroxysmal nocturnal haemoglobinuria considered a concern for thrombosis?

It is associated with altered blood cell composition. Signup and view all the answers

What type of circulation can thrombosis affect in both PV and essential thrombocythaemia?

Both arterial and venous circulation Signup and view all the answers

What is the relationship between PV and essential thrombocythaemia based on their characteristics?

There is significant overlap between the two Signup and view all the answers

Which statement correctly describes thrombosis in the context of PV and essential thrombocythaemia?

Thrombosis can occur in both conditions and in different circulation types Signup and view all the answers

In which condition is it more common for thrombosis to involve both types of circulation?

Both essential thrombocythemia and polycythemia vera Signup and view all the answers

Why might understanding the overlap between PV and essential thrombocythaemia be important?

It can help in identifying treatment options for vascular diseases. Signup and view all the answers

Where is there an excess of thrombosis events?

In the hepatic and portal veins Signup and view all the answers

Which area is NOT mentioned as a site for thrombosis events?

Pulmonary circulation Signup and view all the answers

What is known about the pathogenesis of thrombosis in PNH?

It remains uncertain. Signup and view all the answers

Which circulation is highlighted as having excess thrombosis events along with the hepatic and portal veins?

Splanchnic circulation Signup and view all the answers

What can be inferred about thrombosis in cerebral veins?

It is a major site for thrombosis events. Signup and view all the answers

Study Notes

Blood Homeostasis and Coagulation (MCLS7211)

This course covers blood homeostasis and coagulation, part of a master's program in Clinical Laboratory Sciences.
The material is from the first semester of 2024/2025.
The lecturer is Dr. Ola Karmi, with email address: [email protected].

Heritable Thrombophilia (Lecture 9)

This lecture discusses heritable thrombophilia, including testing for factor V Leiden deficiency.
Testing includes diluting the sample with factor-deficient plasma for APC sensitivity ratio testing.

APC Resistance Testing

APC/SR test involves diluting the test sample using FV-deficient plasma;
APC/SR is calculated as (aPTT of sample + APC (sec) / aPTT of sample without added APC (sec)).
Confirmation is done through DNA analysis.

APC Resistance (Functional Assay)

This is a modified APTT assay to assess APC resistance.
Patient PPP is mixed with FV-deficient substrate to enhance sensitivity.
The modified APTT is measured after adding a specific amount of APC, it should be prolonged.
Genetic testing (PCR analysis of FV mutations) is part of the diagnosis.

Heritable APC Resistance (Not Due to FVL)

Caused by rare mutations (Arg306Thr and Arg306Gly).
A gene haplotype (HR2) mutation (His1299Arg) exists
Co-inheritance of HR2 and FVL increases VTE risk by 3-4 folds.

Von Willebrand Disease vs. Factor V Leiden

Von Willebrand Disease:
- Recurrent bleeding episodes
- Family history
- Increased bleeding time
- Normal or prolonged aPTT
- Normal PT
- Normal platelet count
- Ristocetin cofactor assay shows no platelet aggregation
- Cofactor level <30 IU/dL
Factor V Leiden:
- Unprovoked thromboembolic events
- Family history of thromboembolism
- Normal bleeding time, aPTT, PT, and platelet counts
- Positive Activated protein C resistance assay
- Genetic testing for Factor V Leiden

Prothrombin G20210A Mutation

A single nucleotide change (G20210A) in the 3'UTR of the prothrombin gene.
Found in 2% of the general population, 6% with first VTE episode, and up to 18% with thrombosis history.
Double heterozygosity with FVL is uncommon (1 in 1000 general population and 1-5% with VTE).

Prothrombin G20210A Mutation (Continued)

Heterozygosity is linked with 25% higher prothrombin levels in plasma.
Increased prothrombin plasma levels and a higher risk of VTE
Elevated FII levels increase VTE risk
Three fold risk increase for VTE (G20210A mutation)
DNA analysis (PCR) is used for diagnosis.

A-RFLP-PCR for FII G20210A

A diagnostic technique identifying the G20210A mutation using polymerase chain reaction and restriction fragment length polymorphisms.

Dysfibrinogenemia

A rare condition (0.8% of VTE patients, but high postpartum thrombosis incidence)
Defective thrombin binding to fibrin results in elevated thrombin levels in plasma.
Diagnosis is based on discordance between functional and immunological fibrinogen assay results – functional activity is notably lower than immunological values in patients with a prolonged thrombin time.

Mixed Etiology Thrombophilia

Elevated FVIII levels are a risk factor for venous and arterial thrombosis, especially in non-O blood groups.
Elevated FVIII (>1500 IU/L) is an independent risk factor for VTE.
Increased levels of FIX and FXI above the 90th percentile for the general population also increase VTE risk.

Thrombophilia Screening

Clinical Assessment:
- Personal history
- Family history
- Clinical examination
Risk factor search:
- Age, immobility, trauma, surgery, hormone use, pregnancy, and obesity.
Lab tests:
- Complete blood count (CBC) and platelet counts
- Liver function tests
- Imaging and further investigations.

Thrombophilia Screening (Continued)

First-Line Tests: Coagulation screen (APTT, PT, TT), AT activity, PC, and PS.
Modified Tests: APC/SR, FV Leiden, FII G20210A, lupus inhibitor screen, anticardiolipin assays.
Second-Line Tests: FVIII levels, homocysteine, fibrinogen levels.

Diagnostic Algorithm for Thrombophilia Screening

A multi-step approach for diagnosing thrombophilia in patients with VTE.

Lecture 10: Acquired Thrombophilia

This lecture focuses on acquired (rather than inherited) blood clotting disorders.

Epidemiology of Venous Thromboembolism (VTE)

Deep vein thrombosis (DVT) is common, predominantly affecting the lower limbs.
Annual incidence in Western populations is around 1 per 1000 people.
VTE incidence is age-dependent, increasing with age, with significant rates in the elderly.

Pregnancy and Venous Thromboembolism (continued)

Pregnancy increases risk of VTE, with significant instances in the postpartum period, but also occurring in the antepartum phase, including the first trimester.
Several factors contribute to this risk, including obesity, increased intra-abdominal pressure, decreased fibrinolysis from the placenta, and increased clotting factors.
Delivery, especially emergency caesarean sections, further increase this risk

Immobility and VTE

Prolonged immobility, whether from surgery, illness, or prolonged sitting, greatly increases VTE risk.
Studies have associated prolonged sitting (even in office settings) with venous thrombosis.

Hospital-Acquired Thrombosis and Iatrogenic VTE

Hospital-acquired thrombosis (HAT) can occur within 90 days of admission, often linked to factors like immobility and/or procedures.
Indwelling devices, infections, and certain chemotherapy drugs contribute to VTE risk
Combined oral contraceptives and Hormone Replacement Therapy (HRT) are linked to VTE risk.

Antiphospholipid Syndrome

This is an acquired thrombophilia affecting both arterial and venous systems.
Characterized by recurrent thrombosis or pregnancy complications.
Presence of antiphospholipid antibodies (tested via the lupus anticoagulant test among other tests and markers)

Venous Thromboembolism and Cancer

A well-established link exists between cancer and venous thromboembolism (VTE).
Cancer-related prothrombotic tendencies include tissue factor expression, elevated prothrombin levels, and tumour cell-associated factors.

Thrombotic Risk in Myeloproliferative Diseases

Malignant diseases may increase the risk of thrombosis.
Polycythemia vera (PV) and essential thrombocythemia (ET) result in vascular occlusions (PV untreated and likely in ET).
Acute promyelocytic leukaemia (APL) sometimes exhibits arterial thrombosis, and the use of all-trans retinoic acid might increase the risk.

Inflammation and Thrombosis

Inflammation modifies coagulation factors. It activates procoagulants while down-regulating anticoagulants and fibrinolysis (by activating PAI-1).
Inflammation factors also increase platelet counts and stimulate fibrinogen levels.

Haematological, Non-Malignant Conditions and Thrombosis

A range of conditions associated with blood disorders including PNH, TTP, sickle cell disease influence thrombosis risk.
In PNH, thrombosis occurs often in certain vascular sites such as the hepatic, portal veins, and cerebral veins.
Sickle cell disease is characterized by sickled red blood cell clustering, thrombosis, and often increased prothrombin levels.

Studying That Suits You

Use AI to generate personalized quizzes and flashcards to suit your learning preferences.

Description

This quiz explores the implications of lupus anticoagulant on clot formation, its characteristics, and the relationship with APTT in blood testing. Additionally, it addresses issues related to indwelling venous devices and postoperative patient care. Test your knowledge on this complex topic in hemostasis and thrombosis.